Literature DB >> 10193906

Effects of local application of 5-hydroxytryptamine into the dorsal or median raphe nuclei on haloperidol-induced catalepsy in the rat.

M L Wadenberg1, K A Young, J T Richter, P B Hicks.   

Abstract

The effects of local application of the endogenous brain neurotransmitter 5-hydroxytryptamine (5-HT; serotonin) into the dorsal (DR) or median (MR) raphe nuclei on haloperidol-induced catalepsy (CAT) in rats were studied. Local application of 5-HT (40 microg, -10 min) into the DR or MR, respectively, produced a significant reversal of haloperidol-induced CAT. Lower doses (5 or 25 microg) of 5-HT were ineffective. Compared to previous studies using the selective 5-HT1A receptor agonist 8-OH-DPAT, the non-selective endogenous serotonin receptor agonist 5-HT was significantly less potent in this paradigm. Furthermore, the observed anticataleptic effect of 5-HT was seen following injections into both DR or MR nuclei. The reversal of CAT by local application of 5-HT (40 microg) into the DR was significant also at 70 min after 5-HT administration, with the same tendency for 5-HT injections into the MR. At this time interval, other serotonergic behavioral symptoms like head twitches and wet-dog shakes also emerged. The early reversal of CAT by local 5-HT administration into the MR is in all probability mediated via stimulation of 5-HT1A autoreceptors on raphe serotonergic cell bodies. The reversal of CAT following 5-HT injections into the DR might alternatively be mediated via functional mechanisms other than stimulation of 5-HT1A autoreceptors. The anticataleptic effects observed at the later observation time could be due to stimulation of postsynaptic 5-HT2 receptors following diffusion of 5-HT into 5-HT2 receptor rich areas of the brain.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10193906     DOI: 10.1016/s0028-3908(98)00162-2

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  7 in total

Review 1.  Therapeutic role of 5-HT1A receptors in the treatment of schizophrenia and Parkinson's disease.

Authors:  Yukihiro Ohno
Journal:  CNS Neurosci Ther       Date:  2010-11-21       Impact factor: 5.243

Review 2.  Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties.

Authors:  Adrian Newman-Tancredi; Mark S Kleven
Journal:  Psychopharmacology (Berl)       Date:  2011-03-11       Impact factor: 4.530

3.  Improving the Treatment of Parkinson's Disease: A Novel Approach by Modulating 5-HT(1A) Receptors.

Authors:  Saki Shimizu; Yukihiro Ohno
Journal:  Aging Dis       Date:  2012-11-29       Impact factor: 6.745

4.  Comparison of hippocampal G protein activation by 5-HT(1A) receptor agonists and the atypical antipsychotics clozapine and S16924.

Authors:  A Newman-Tancredi; J-M Rivet; D Cussac; M Touzard; C Chaput; L Marini; M J Millan
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-08-16       Impact factor: 3.000

5.  Postsynaptic 5-HT1A receptor stimulation increases motor activity in the 6-hydroxydopamine-lesioned rat: implications for treating Parkinson's disease.

Authors:  Laurence Mignon; William A Wolf
Journal:  Psychopharmacology (Berl)       Date:  2007-01-31       Impact factor: 4.415

Review 6.  Antipsychotic Treatment of Behavioral and Psychological Symptoms of Dementia (BPSD): Management of Extrapyramidal Side Effects.

Authors:  Yukihiro Ohno; Naofumi Kunisawa; Saki Shimizu
Journal:  Front Pharmacol       Date:  2019-09-17       Impact factor: 5.810

Review 7.  Pathophysiological Mechanisms of Antipsychotic-Induced Parkinsonism.

Authors:  Elena E Vaiman; Natalia A Shnayder; Aiperi K Khasanova; Anna I Strelnik; Arseny J Gayduk; Mustafa Al-Zamil; Margarita R Sapronova; Natalia G Zhukova; Daria A Smirnova; Regina F Nasyrova
Journal:  Biomedicines       Date:  2022-08-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.